ETH-LAD
| Clinical data | |
|---|---|
| Other names | ETH-LAD; ETHLAD; 6-Ethyl-6-nor-lysergic acid diethylamide; 6-Ethyl-6-nor-LSD; N(6)-Ethyl-nor-LSD; 9,10-Didehydro-N,N,6-triethylergoline-8β-carboxamide |
| Routes of administration | Oral |
| Drug class | Serotonin receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | 15 minutes–1 hour |
| Duration of action | 8–12 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H27N3O |
| Molar mass | 337.467 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
ETH-LAD, or ETHLAD, also known as 6-ethyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD; also known as METH-LAD). It is slightly more potent than LSD and is among the most potent psychedelics known. The drug is taken orally.
It acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor. In addition, it binds to dopamine receptors. The drug produces psychedelic-like effects in animals. It is closely structurally related to LSD and to other psychedelic lysergamides like PRO-LAD and AL-LAD.
ETH-LAD was first described in the scientific literature by 1976. Its effects in humans were assessed and reported by Alexander Shulgin in the 1980s and 1990s. The drug was encountered as a novel recreational designer drug in Europe by 2016. In addition, a prodrug of ETH-LAD, 1P-ETH-LAD, has been developed and encountered as a designer drug.